Feed - Buzzberg

08:00
Jul 21 ◎

DHR FY2026 Q2 Watch

Danaher Corporation (DHR) FY2026 Q2 Earnings Call

MASI DHR ▾

Rainer Blair

Masimo was acquired by Danaher; management cites high single-digit growth and early operating review successes, signaling strong performance and synergy potential.

"we closed our acquisition of Massimo in early June, ahead of our initial expectations. We expect Massimo to be immediately accretive both strategically and to adjusted EPS."

MASI WATCH

Rainer Blair

Guidance raised for full-year EPS, core growth expected to exit at mid-single digits in Q4, underpinned by improving end markets and productivity initiatives.

"we delivered a solid second quarter with better than expected revenue, earnings, and cash flow. We were particularly pleased to see an acceleration in core growth versus the first quarter"

DHR WATCH

HIGH

08:00
Apr 21 ◎

DHR FY2026 Q1 Watch

Danaher Corporation (DHR) FY2026 Q1 Earnings Call

MASI DHR ▾

Reiner Blair

Danaher expects Masimo’s financial profile to improve under DBS, with confirmed cost and revenue synergy targets, indicating confidence in value creation post-close.

"We expect Massimo to be accretive to adjusted diluted net earnings for common share in the first full year post acquisition and to deliver high single digit return on invested capital by the fifth full year of our ownership."

MASI WATCH

Reiner Blair

Management raised EPS guidance despite a softer respiratory season, citing better-than-expected underlying momentum across bioprocessing and life sciences, and expects growth to accelerate in H2 as headwinds fade.

"we're raising our full-year adjusted diluted net EPS guidance to a range of $8.35 to $8.55 versus our previous range of $8.35 to $8.50."

DHR WATCH

HIGH

08:00
Jan 28 ◎

DHR FY2025 Q4 Watch

Danaher Corporation (DHR) FY2025 Q4 Earnings Call

08:00
Oct 21 ◎

DHR FY2025 Q3 Watch

Danaher Corporation (DHR) FY2025 Q3 Earnings Call

DHR ▾

Reiner Blair

Management provided an above-consensus initial 2026 guide with 3-6% core growth and high single-digit EPS growth, supported by cost actions and margin expansion, indicating confidence in secular bioprocessing demand and a modest recovery in end markets.

"For the full year 2026, we expect core revenue growth in the 3% to 6% range, as we are assuming modest recovery across our end markets."

DHR WATCH

HIGH

Feed — Buzzberg